Sex, Drugs, and Adverse Drug Reactions: Sex Differences in Laboratory Monitoring Outcomes After Initiation of Renin-Angiotensin-Aldosterone-System Inhibition Therapy

Circ Cardiovasc Qual Outcomes. 2020 Sep;13(9):e007045. doi: 10.1161/CIRCOUTCOMES.120.007045. Epub 2020 Sep 2.

Authors

Sandra Marie Dumanski^{1

2

3}, Sofia Bano Ahmed^{1

2

3}

Affiliations

¹ Department of Medicine, University of Calgary, Alberta, Canada (S.M.D., S.B.A.).
² Libin Cardiovascular Institute of Alberta, Calgary, Canada (S.M.D., S.B.A.).
³ Alberta Kidney Disease Network, Calgary, Canada (S.M.D., S.B.A.).

PMID: 32873053
DOI: 10.1161/CIRCOUTCOMES.120.007045

No abstract available

Keywords: RAAS inhibition; acute kidney injury; blood pressure; gender; hyperkalemia; hypertension; sex differences.

Publication types

Editorial
Comment

MeSH terms

Aldosterone
Angiotensins
Female
Humans
Kidney
Laboratories
Male
Pharmaceutical Preparations*
Potassium
Renin
Renin-Angiotensin System*
Sex Characteristics
United States

Substances

Angiotensins
Pharmaceutical Preparations
Aldosterone
Renin
Potassium